

# Recombinant Human soluble Receptor Activator of Nuclear Factor kappa-B Receptor/TNFRSF11A

### **Information**

| Gene ID                    | 8792  |                        |  |
|----------------------------|---|------------------------|--|
| Accession #                | Q9Y6Q6  |                        |  |
| Alternate Names            |   |                        |  |
| Source                     | Escherichia coli.   | Burrown                |  |
| M.Wt                       | Approximately 19.1 kDa, a single non-glycosylated polype 174 amino acids.   | otide chain containing |  |
| AA Sequence                | QIAPPCTSEK HYEHLGRCCN KCEPGKYMS <mark>S KCTTT</mark> SDSVC LPCGPDEYLD<br>SWNEEDKCLL HKVCDTGKAL VAVVAGNSTT PRRCACTAGY<br>HWSQDCECCR RNTECAPGLG AQHPLQLNKD TVCKPCLAGY<br>FSDAFSSTDK CRPWTNCTFL GKRVEHHGTE KSDAVCSSSL PARK   |                        |  |
| Appearance                 | Sterile Filtered White lyophilized (freeze-dried) powder.   |                        |  |
| Stability & Storage        | Use a manual defrost freezer and avoid repeated freeze-thaw cycles<br>- 12 months from date of receipt, -20 to -70 °C as supplied<br>- 1 month, 2 to 8 °C under sterile conditions after reconstitution<br>- 3 months, -20 to -70 °C under sterile conditions after reconstitution  |                        |  |
| Formulation                | Lyophilized from a 0.2 $\mu$ m filtered concentrated solution in 20 mM Tris-HCl, pH 8.0, 150mM NaCl.  |                        |  |
| Reconstitution             | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at $\leq$ -20 °C. Further dilutions should be made in appropriate buffered solutions. |                        |  |
| <b>Biological Activity</b> | Fully biologically active when compared to standard. The ED as determined by its ability to inhibit sRANK Ligand induced nuclear factor kappa B(NFkappaB) in RAW 264.7 cells is less than 50 ng/ml, corresponding to a specific activity of > $2.0 \times 10$ IU/mg in the presence of 15 ng/ml of recombinant sRANK Ligand.  |                        |  |
| Shipping Condition         | Gel pack.   | <u>.</u>               |  |
| Handling                   | Centrifuge the vial prior to opening.   | 3 ne unrown            |  |
| Usage                      | Usage For Research Use Only! Not to be used in humans.  |                        |  |
| EXOLO.                     | Alter Steel   |                        |  |

## Components and Storage

| Components                                | 100µg | 500µg |  |
|---|-------|-------|--|
| <b>Recombinant Human soluble Receptor</b> |       |       |  |
| Activator of Nuclear Factor kappa-B       | 100µg | 500µg |  |
| Receptor/TNFRSF11A                        |       |       |  |

Use a manual defrost freezer and avoid repeated freeze-thaw cycles

- 12 months from date of receipt, -20 to -70 °C as supplied
- 1 month, 2 to 8 °C under sterile conditions after reconstitution
- 3 months, -20 to -70 °C under sterile conditions after reconstitution

| Quality Control | Paran   |  |  |
|-----------------|---|--|--|
| Purity          | > 98 % by SDS-PAGE and HPLC analyses.             | President for and the and  |  |
| Endotoxin       | Less than 0.1 EU/ $_{\mu}$ g of rHusRANK Receptor | than 0.1 EU/ $\mu$ g of rHusRANK Receptor as determined by LAL method. |  |

#### Description

#### Reference



APENER BIO





